Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab vs Itraconazole in ABPA
NCT05129033Unknown
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Nov 2021
- Primary completion
- Jun 2023
- Modality
- Monoclonal Antibodies
01
Overview
Randomised, open-label trial of omalizumab in allergic bronchopulmonary aspergillosis (ABPA) (2 arms), sponsored by Zhongshan Hospital, Fudan University. Primary endpoint: Incidence of exacerbation. Status: unknown.
02
Drugs
omalizumab
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)
Beyond the preview
Go deeper on NCT05129033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05129033.